Literature DB >> 7947371

The ever expanding spectrum of ischemic left ventricular dysfunction.

L H Opie1.   

Abstract

Ischemic left ventricular (LV) dysfunction includes a number of discrete entities, such as acute LV failure in angina, acute myocardial infarction, and ischemic cardiomyopathy. Recently, new entities have arisen to expand the spectrum of ischemic LV function. These include postinfarct diastolic dysfunction, stunning, hibernation, and preconditioning. The tantalizing possibility exists that several of these states can coexist. There are widely differing underlying pathophysiologic states. Hence it is not easy to be dogmatic about whether a given group of therapeutic agents, such as the calcium antagonists, may be beneficial in ischemic LV dysfunction. Nonetheless, there is experimental evidence that calcium antagonists may benefit the specific entity of stunning and clinical evidence that they benefit postinfarct ischemic LV diastolic dysfunction. These agents, as a group, should be evaluated in reperfusion and postinfarct dysfunctional syndromes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947371     DOI: 10.1007/bf00877313

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  38 in total

Review 1.  Cardiac metabolism--emergence, decline, and resurgence. Part I.

Authors:  L H Opie
Journal:  Cardiovasc Res       Date:  1992-08       Impact factor: 10.787

Review 2.  Myocardial 'stunning' in man.

Authors:  R Bolli
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

Review 3.  Hibernation and myocardial ischemia: clinical detection by positron emission tomography.

Authors:  N G Uren; P G Camici
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

4.  Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. The Danish Study Group on Verapamil in Myocardial Infarction.

Authors:  J F Hansen
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

Review 5.  Reperfusion injury and its pharmacologic modification.

Authors:  L H Opie
Journal:  Circulation       Date:  1989-10       Impact factor: 29.690

6.  Myocardial ischemia--observations, definitions and speculations.

Authors: 
Journal:  J Mol Cell Cardiol       Date:  1970-12       Impact factor: 5.000

7.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.

Authors:  J F Setaro; B L Zaret; D S Schulman; H R Black; R Soufer
Journal:  Am J Cardiol       Date:  1990-10-15       Impact factor: 2.778

8.  Biochemical and structural correlates in unloaded and reloaded cat myocardium.

Authors:  R L Kent; C E Uboh; E W Thompson; S S Gordon; T A Marino; J K Hoober; G Cooper
Journal:  J Mol Cell Cardiol       Date:  1985-02       Impact factor: 5.000

9.  The calcium antagonist nisoldipine improves the functional recovery of reperfused myocardium only when given before ischemia.

Authors:  T Ehring; M Böhm; G Heusch
Journal:  J Cardiovasc Pharmacol       Date:  1992-07       Impact factor: 3.105

10.  Failure of calcium channel blockers to improve ventricular relaxation in humans.

Authors:  R A Nishimura; R S Schwartz; D R Holmes; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1993-01       Impact factor: 24.094

View more
  2 in total

1.  Tissue Doppler imaging for detection of myocardial ischemia: are we there yet?

Authors:  Douwe E Atsma
Journal:  Int J Cardiovasc Imaging       Date:  2003-08       Impact factor: 2.357

2.  Myocardial stunning by gated SPECT: An old tool reinvented in a stunning turn.

Authors:  Wael A AlJaroudi; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-11-14       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.